1. Compared with spironolactone, BAY 94-8862 resulted in a significantly smaller increase in serum potassium concentration (0.04–0.30 mmol/L vs 0.45 mmol/L, P < 0.0001–0.0107).2. The incidence of hyperkalemia was lower in the BAY 94-8862 group (5.3%) compared to the spironolactone group (12.7%, P = 0.048).3. BAY 94-8862 reduced levels of BNP, NT-ProBNP, and albuminuria, at least as much as spironolactone.4. Adverse events associated with BAY 94-8862 were infrequent and mostly mild. Here, NPPB is linked to Hyperkalemia.